TMEM132A

Across TCGA pan-cancer cohorts, TMEM132A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM132A data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM132A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM132A expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where TMEM132A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	1.000	0.874	.003	12	view →
LSCC	DFS	Tertile	III,IV	1.000	0.403	.013	11	view →
LUAD	OS	Tertile	All	0.778	0.967	.020	9	view →
PDAC	DFS	Tertile	All	0.248	0.565	.032	4	view →
GBM	OS	Median	All	0.873	0.755	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM132A–HNSC (DFS)

Open the HNSC breakdown →